Epstein–Barr virus infection during pregnancy and the risk of adverse pregnancy outcome
Objectives To study the association between Epstein–Barr virus (EBV) antibody status in early pregnancy and pregnancy outcomes including fetal death, length of gestation and fetal weight and length at birth. Design Nested control study. Setting Population based health registers. Population The s...
Gespeichert in:
| Veröffentlicht in: | BJOG : an international journal of obstetrics and gynaecology 2005-12, Vol.112 (12), p.1620-1624 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1624 |
|---|---|
| container_issue | 12 |
| container_start_page | 1620 |
| container_title | BJOG : an international journal of obstetrics and gynaecology |
| container_volume | 112 |
| creator | Eskild, Anne Bruu, Anne‐Lise Stray‐Pedersen, Babill Jenum, Pål |
| description | Objectives To study the association between Epstein–Barr virus (EBV) antibody status in early pregnancy and pregnancy outcomes including fetal death, length of gestation and fetal weight and length at birth.
Design Nested control study.
Setting Population based health registers.
Population The source population comprised 35,940 pregnant women. Cases were all (280) women with fetal death and a random sample of 940 women with a live born child.
Method Information on pregnancy outcome was obtained from the Norwegian Medical Birth Registry. Serum samples from the first trimester were tested for EBV antibodies. In women seronegative for EBV, further serum from late pregnancy was analysed to detect seroconversion.
Main outcome measures Vital status, length of gestation, weight and length at birth.
Results There was no association between EBV antibody status and fetal death. Women with significant EBV reactivation had a significantly shorter duration of pregnancy, and associated lighter babies, compared with women without significant reactivation (stillborn: 176 vs 197 days, P= 0.16, and live born: 271 vs 279 days, P= 0.03, respectively).
Conclusion Significant reactivation of EBV infection during pregnancy may influence pregnancy duration. |
| doi_str_mv | 10.1111/j.1471-0528.2005.00764.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68824173</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1038025621</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5764-164ee0eb79d04bb808039153b1785e35f720cc215b7945c4c2a865c3b078db1d3</originalsourceid><addsrcrecordid>eNqN0c1u1DAQB3ALgWgpvAKykOCWMP52Lki0Ki2oUi9w4GQ5jlO8ZJPFTkr3xjvwhn2SOrurtuKy-GJL_s1oRn-EMIGS5PN-URKuSAGC6pICiBJASV7ePEGH9x9PN28ogFF9gF6ktAAgkgJ7jg6IZCCE5Ifo--kqjT70t3_-HtsY8XWIU8Khb70bw9DjZoqhv8Kr6K9627s1tn2Dxx8ex5B-4qHFtrn2MflHYphGNyz9S_SstV3yr3b3Efr26fTryXlxcXn2-eTjReFEnrkgknsPvlZVA7yuNWhgFRGsJkoLz0SrKDhHiciCC8cdtVoKx2pQuqlJw47Qu23fVRx-TT6NZhmS811nez9MyUitKSeK7YWUgMxSZvjmH7gYptjnJQylQlJaEbofKV3tQ4RDpTLSW-TikFL0rVnFsLRxbQiYOW6zMHOqZk7VzHGbTdzmJpe-3vWf6qVvHgp3-WbwdgdscrZrY04opAenaMUpm1f-sHW_Q-fX_z2AOf5yuXmyO_pXw9Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>225614097</pqid></control><display><type>article</type><title>Epstein–Barr virus infection during pregnancy and the risk of adverse pregnancy outcome</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Eskild, Anne ; Bruu, Anne‐Lise ; Stray‐Pedersen, Babill ; Jenum, Pål</creator><creatorcontrib>Eskild, Anne ; Bruu, Anne‐Lise ; Stray‐Pedersen, Babill ; Jenum, Pål</creatorcontrib><description>Objectives To study the association between Epstein–Barr virus (EBV) antibody status in early pregnancy and pregnancy outcomes including fetal death, length of gestation and fetal weight and length at birth.
Design Nested control study.
Setting Population based health registers.
Population The source population comprised 35,940 pregnant women. Cases were all (280) women with fetal death and a random sample of 940 women with a live born child.
Method Information on pregnancy outcome was obtained from the Norwegian Medical Birth Registry. Serum samples from the first trimester were tested for EBV antibodies. In women seronegative for EBV, further serum from late pregnancy was analysed to detect seroconversion.
Main outcome measures Vital status, length of gestation, weight and length at birth.
Results There was no association between EBV antibody status and fetal death. Women with significant EBV reactivation had a significantly shorter duration of pregnancy, and associated lighter babies, compared with women without significant reactivation (stillborn: 176 vs 197 days, P= 0.16, and live born: 271 vs 279 days, P= 0.03, respectively).
Conclusion Significant reactivation of EBV infection during pregnancy may influence pregnancy duration.</description><identifier>ISSN: 1470-0328</identifier><identifier>EISSN: 1471-0528</identifier><identifier>DOI: 10.1111/j.1471-0528.2005.00764.x</identifier><identifier>PMID: 16305564</identifier><identifier>CODEN: BIOGFQ</identifier><language>eng</language><publisher>Oxford, UK and Malden, USA: Blackwell Science Ltd</publisher><subject>Adolescent ; Adult ; Antibodies, Viral - blood ; Biological and medical sciences ; Birth Weight ; Case-Control Studies ; Epstein-Barr virus ; Epstein-Barr Virus Infections - complications ; Female ; Fetal Death - virology ; Gynecology. Andrology. Obstetrics ; Herpesvirus 4, Human - immunology ; Humans ; Infectious diseases ; Maternal Age ; Medical sciences ; Middle Aged ; Parity ; Pregnancy ; Pregnancy Complications, Infectious - virology ; Pregnancy Outcome ; Pregnancy Trimester, First ; Risk Factors ; Viruses</subject><ispartof>BJOG : an international journal of obstetrics and gynaecology, 2005-12, Vol.112 (12), p.1620-1624</ispartof><rights>2006 INIST-CNRS</rights><rights>RCOG 2005 BJOG: an International Journal of Obstetrics and Gynaecology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5764-164ee0eb79d04bb808039153b1785e35f720cc215b7945c4c2a865c3b078db1d3</citedby><cites>FETCH-LOGICAL-c5764-164ee0eb79d04bb808039153b1785e35f720cc215b7945c4c2a865c3b078db1d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1471-0528.2005.00764.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1471-0528.2005.00764.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17294236$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16305564$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Eskild, Anne</creatorcontrib><creatorcontrib>Bruu, Anne‐Lise</creatorcontrib><creatorcontrib>Stray‐Pedersen, Babill</creatorcontrib><creatorcontrib>Jenum, Pål</creatorcontrib><title>Epstein–Barr virus infection during pregnancy and the risk of adverse pregnancy outcome</title><title>BJOG : an international journal of obstetrics and gynaecology</title><addtitle>BJOG</addtitle><description>Objectives To study the association between Epstein–Barr virus (EBV) antibody status in early pregnancy and pregnancy outcomes including fetal death, length of gestation and fetal weight and length at birth.
Design Nested control study.
Setting Population based health registers.
Population The source population comprised 35,940 pregnant women. Cases were all (280) women with fetal death and a random sample of 940 women with a live born child.
Method Information on pregnancy outcome was obtained from the Norwegian Medical Birth Registry. Serum samples from the first trimester were tested for EBV antibodies. In women seronegative for EBV, further serum from late pregnancy was analysed to detect seroconversion.
Main outcome measures Vital status, length of gestation, weight and length at birth.
Results There was no association between EBV antibody status and fetal death. Women with significant EBV reactivation had a significantly shorter duration of pregnancy, and associated lighter babies, compared with women without significant reactivation (stillborn: 176 vs 197 days, P= 0.16, and live born: 271 vs 279 days, P= 0.03, respectively).
Conclusion Significant reactivation of EBV infection during pregnancy may influence pregnancy duration.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antibodies, Viral - blood</subject><subject>Biological and medical sciences</subject><subject>Birth Weight</subject><subject>Case-Control Studies</subject><subject>Epstein-Barr virus</subject><subject>Epstein-Barr Virus Infections - complications</subject><subject>Female</subject><subject>Fetal Death - virology</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Herpesvirus 4, Human - immunology</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Maternal Age</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Parity</subject><subject>Pregnancy</subject><subject>Pregnancy Complications, Infectious - virology</subject><subject>Pregnancy Outcome</subject><subject>Pregnancy Trimester, First</subject><subject>Risk Factors</subject><subject>Viruses</subject><issn>1470-0328</issn><issn>1471-0528</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqN0c1u1DAQB3ALgWgpvAKykOCWMP52Lki0Ki2oUi9w4GQ5jlO8ZJPFTkr3xjvwhn2SOrurtuKy-GJL_s1oRn-EMIGS5PN-URKuSAGC6pICiBJASV7ePEGH9x9PN28ogFF9gF6ktAAgkgJ7jg6IZCCE5Ifo--kqjT70t3_-HtsY8XWIU8Khb70bw9DjZoqhv8Kr6K9627s1tn2Dxx8ex5B-4qHFtrn2MflHYphGNyz9S_SstV3yr3b3Efr26fTryXlxcXn2-eTjReFEnrkgknsPvlZVA7yuNWhgFRGsJkoLz0SrKDhHiciCC8cdtVoKx2pQuqlJw47Qu23fVRx-TT6NZhmS811nez9MyUitKSeK7YWUgMxSZvjmH7gYptjnJQylQlJaEbofKV3tQ4RDpTLSW-TikFL0rVnFsLRxbQiYOW6zMHOqZk7VzHGbTdzmJpe-3vWf6qVvHgp3-WbwdgdscrZrY04opAenaMUpm1f-sHW_Q-fX_z2AOf5yuXmyO_pXw9Y</recordid><startdate>200512</startdate><enddate>200512</enddate><creator>Eskild, Anne</creator><creator>Bruu, Anne‐Lise</creator><creator>Stray‐Pedersen, Babill</creator><creator>Jenum, Pål</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><general>Wiley Subscription Services, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>ASE</scope><scope>FPQ</scope><scope>K6X</scope><scope>K9.</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200512</creationdate><title>Epstein–Barr virus infection during pregnancy and the risk of adverse pregnancy outcome</title><author>Eskild, Anne ; Bruu, Anne‐Lise ; Stray‐Pedersen, Babill ; Jenum, Pål</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5764-164ee0eb79d04bb808039153b1785e35f720cc215b7945c4c2a865c3b078db1d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antibodies, Viral - blood</topic><topic>Biological and medical sciences</topic><topic>Birth Weight</topic><topic>Case-Control Studies</topic><topic>Epstein-Barr virus</topic><topic>Epstein-Barr Virus Infections - complications</topic><topic>Female</topic><topic>Fetal Death - virology</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Herpesvirus 4, Human - immunology</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Maternal Age</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Parity</topic><topic>Pregnancy</topic><topic>Pregnancy Complications, Infectious - virology</topic><topic>Pregnancy Outcome</topic><topic>Pregnancy Trimester, First</topic><topic>Risk Factors</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eskild, Anne</creatorcontrib><creatorcontrib>Bruu, Anne‐Lise</creatorcontrib><creatorcontrib>Stray‐Pedersen, Babill</creatorcontrib><creatorcontrib>Jenum, Pål</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>British Nursing Index</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>BJOG : an international journal of obstetrics and gynaecology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eskild, Anne</au><au>Bruu, Anne‐Lise</au><au>Stray‐Pedersen, Babill</au><au>Jenum, Pål</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Epstein–Barr virus infection during pregnancy and the risk of adverse pregnancy outcome</atitle><jtitle>BJOG : an international journal of obstetrics and gynaecology</jtitle><addtitle>BJOG</addtitle><date>2005-12</date><risdate>2005</risdate><volume>112</volume><issue>12</issue><spage>1620</spage><epage>1624</epage><pages>1620-1624</pages><issn>1470-0328</issn><eissn>1471-0528</eissn><coden>BIOGFQ</coden><abstract>Objectives To study the association between Epstein–Barr virus (EBV) antibody status in early pregnancy and pregnancy outcomes including fetal death, length of gestation and fetal weight and length at birth.
Design Nested control study.
Setting Population based health registers.
Population The source population comprised 35,940 pregnant women. Cases were all (280) women with fetal death and a random sample of 940 women with a live born child.
Method Information on pregnancy outcome was obtained from the Norwegian Medical Birth Registry. Serum samples from the first trimester were tested for EBV antibodies. In women seronegative for EBV, further serum from late pregnancy was analysed to detect seroconversion.
Main outcome measures Vital status, length of gestation, weight and length at birth.
Results There was no association between EBV antibody status and fetal death. Women with significant EBV reactivation had a significantly shorter duration of pregnancy, and associated lighter babies, compared with women without significant reactivation (stillborn: 176 vs 197 days, P= 0.16, and live born: 271 vs 279 days, P= 0.03, respectively).
Conclusion Significant reactivation of EBV infection during pregnancy may influence pregnancy duration.</abstract><cop>Oxford, UK and Malden, USA</cop><pub>Blackwell Science Ltd</pub><pmid>16305564</pmid><doi>10.1111/j.1471-0528.2005.00764.x</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1470-0328 |
| ispartof | BJOG : an international journal of obstetrics and gynaecology, 2005-12, Vol.112 (12), p.1620-1624 |
| issn | 1470-0328 1471-0528 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68824173 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adolescent Adult Antibodies, Viral - blood Biological and medical sciences Birth Weight Case-Control Studies Epstein-Barr virus Epstein-Barr Virus Infections - complications Female Fetal Death - virology Gynecology. Andrology. Obstetrics Herpesvirus 4, Human - immunology Humans Infectious diseases Maternal Age Medical sciences Middle Aged Parity Pregnancy Pregnancy Complications, Infectious - virology Pregnancy Outcome Pregnancy Trimester, First Risk Factors Viruses |
| title | Epstein–Barr virus infection during pregnancy and the risk of adverse pregnancy outcome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T22%3A08%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Epstein%E2%80%93Barr%20virus%20infection%20during%20pregnancy%20and%20the%20risk%20of%20adverse%20pregnancy%20outcome&rft.jtitle=BJOG%20:%20an%20international%20journal%20of%20obstetrics%20and%20gynaecology&rft.au=Eskild,%20Anne&rft.date=2005-12&rft.volume=112&rft.issue=12&rft.spage=1620&rft.epage=1624&rft.pages=1620-1624&rft.issn=1470-0328&rft.eissn=1471-0528&rft.coden=BIOGFQ&rft_id=info:doi/10.1111/j.1471-0528.2005.00764.x&rft_dat=%3Cproquest_cross%3E1038025621%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=225614097&rft_id=info:pmid/16305564&rfr_iscdi=true |